TVGN Company Profile and Key Details

The stock is currently mid-range between its 52-week high and low $0.36 and $1.92. With a market capitalization of about $76.36 million, Tevogen Bio Holdings Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.81). Key stats such as the average daily volume over the past year has been around 815.60 thousand shares, volume is running light vs its 52-week average. Headquartered in Warren, NJ, Tevogen Bio Holdings Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ryan H. Saadi, the company employs approximately 18 people and listed since January 05, 2022. Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.

TVGN has shown weak momentum, losing -11.7% over the past week and -49.93% over the past quarter, though year-to-date performance is down -63.14%. Short-term trend indicators are bullishly aligned (SMA20 -9.0%, SMA50 -25.88%, SMA200 -58.69%). The stock’s 14-day RSI is 38.58 (weak momentum), while the ATR of 0.04 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -80.22% below its high and over 4.89% above its low. Average 10-day trading volume of 588.00 thousand shares is below the 3-month average of 805.59 thousand, indicating normal recent market interest.

Tevogen Bio Holdings Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.01. This means the shares are trading below this model’s fair value.

Tevogen Bio Holdings Inc. has 196.70 million shares outstanding. The public float is 22.57 million shares, elevated short interest at 4.82% of float. This equals 2.99 million shares. The short ratio is 2.32 days. Institutional investors hold 12.44% of the float. Insiders own 79.36%. Saadi Ryan H. holds 116.81 million shares, Desai Kirti has 9.70 million shares and Flomenberg Neal has 3.60 million shares.

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $5.00. The high target offers 2531.58% upside. The low target suggests 1215.79% downside. The mean target is $9.38. This offers 2368.42% upside. Tevogen Bio Holdings Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by -50.66%. The prior quarter beat by -40.0%. Over the last six quarters, Apple has recorded several small beats. These include 56.06% in April 02, 2025.

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shares are down -63.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Tevogen Bio Holdings Inc. trading at a premium to the broader market with a P/E of -2.4. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.38, suggesting 2370.37% upside. Our AI forecast model points to short-term weakness (-5.19% over two weeks), a medium-term rise (131.76% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Tevogen Bio Holdings Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.19%, with price expected at $0.36 by January 02, 2026, within a range of $0.32 to $0.39 3-Month Outlook: Projected rise of 131.76%, reaching $0.88 by March 19, 2026, with a range of $0.55 to $0.98. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by December 18, 2026, within a range of $0.00 to $0.31.

Tevogen Bio Holdings Inc. trades at a P/E ratio of -2.4, slightly below the S&P 500 average, with a price-to-sales ratio of 190.23 and a price-to-book ratio of -9.51 indicating negative book value, which may reflect financial stress. The P/FCF stands at -5.72, also below market averages.